|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
50687179
???header.onlineuser??? :
241
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"ochsenreither"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立成功大學 |
2024-09 |
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
|
Toullec;C;Seo;S;Robinson;A, G.;Chou;H-H;Salman;P;Ghiringhelli;F;Ozyilkan;O;Rojas;C, I.;Sendur;M, A. N.;Tourneau, Le;C;Yen;C, J.;Aksoy;S;Ochsenreither;S;Ruiz;Yanez, E. P.;Rha;S, Y.;Shapira-Frommer;R;Liu;Q;Plessis, Du;M;Keenan;T;Hsu;C-H |
| 國立成功大學 |
2024-06 |
Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
|
Hsu;C-H;Dziadziuszko;R;Abreo, Gomez;D, A.;Aksoy;S;Martin, Gil;M;Roderburg;C;Yen;C, J.;Arican;A;Cassier;P;Im;S-A;Kim;S-B;Kudo;T;Ochsenreither;S;Sendur;M, A. N.;Yonemori;K;Rojas;C, I.;Liu;Q;Keenan;T;Healy;J;Kwiatkowski;M |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
